Skip to main content
. 2024 Feb 1;19(2):e0293264. doi: 10.1371/journal.pone.0293264

Table 1. Input parameters for the base-case analysis.

Category. Description Value References
Cost R&D costs associated with the development of antineoplastic and immunomodulating agents, capitalized and risk adjusted. Unadjusted for inflation and currency change. €4937.4 million Wouters et al. (2020) [17]
Cost of manufacturing per gram of mAbs €55 Ou Yang et al. (2019) [24]
R&D costs associated with each new indication. €347 million Nosengo (2016) [18]
Incidence rate per 100,000 Multiple myeloma 7.6 IARC [1]
Melanoma 21.7 IARC [1]
Lung Cancer 69.5 IARC [1]
Head and neck cancer 21.8 IARC [1]
Hodgkin Lymphoma 2.5 IARC [1]
Bladder cancer 26.3 IARC [1]
Gastric and Oesophagus cancer 32.1 IARC [1]
Cervical cancer 13.3 IARC [1]
Non-Hodgkin Lymphoma 19.2 IARC [1]
Liver cancer 14.4 IARC [1]
Non melanoma skin cancer 80.3 IARC [1]
Kidney cancer 19.3 IARC [1]
Oesophagus cancers 8.0 IARC [1]
Corpus uteri cancer 33.7 IARC [1]
Colorectum cancer 68.1 IARC [1]
Breast cancer 142.0 IARC [1]
Patent expiry (year) Daratumumab 2025 Busse & Lüftner (2019) [21]
Pembrolizumab 2028 Busse & Lüftner (2019) [21]
Profit margin (in %) Profit margin 20% Uyl-de Groot & Löwenberg (2018) [9]

mAbs: Monoclonal antibodies.